Medtronic’s Upcoming Earnings Report Forecasts Positive Growth
Wall Street analysts anticipate that Medtronic (MDT) will announce quarterly earnings of $1.31 per share, which marks a 4% increase from the same timeframe last year. Additionally, revenues are expected to reach $8.86 billion, reflecting a year-over-year growth of 5.4%. Notably, the consensus estimate for earnings per share (EPS) has seen a slight downward adjustment of 0.1% over the past month, highlighting a revision in the analysts’ initial projections. It is essential to consider such changes in earnings estimates, as they can significantly influence how investors might react once the earnings report is released. Research indicates a strong correlation between earnings estimate revisions and short-term stock price movements.
Importance of Analysts’ Earnings Estimates
While many investors rely on consensus earnings and revenue forecasts to gauge a company’s quarterly performance, examining the projections for specific key metrics can offer deeper insights. With this perspective, let us review the average expectations for various Medtronic metrics as analyzed by Wall Street experts.
Projected Revenue Metrics for Medtronic
Analysts predict that Medtronic’s ‘Net Sales- Worldwide Revenue- Diabetes’ will reach approximately $749.45 million, reflecting a growth of 9.3% from the previous year. For ‘Net Sales- Worldwide Revenue- Neuroscience,’ the consensus estimate stands at $2.49 billion, suggesting a 1.5% increase compared to the same quarter last year. The projections for ‘Net Sales- Worldwide Revenue- Cardiovascular’ indicate expected revenues of $3.36 billion, which translates to an 8.5% rise from the prior-year quarter. Additionally, estimates for ‘Net Sales- Worldwide Revenue- Medical Surgical’ are set at $2.24 billion, pointing to a 5.4% growth year-over-year.
In terms of U.S. revenues, analysts foresee ‘Net Sales- U.S. Revenue’ reaching $4.53 billion, marking a 5.3% increase from the previous year. However, the projection for ‘Net Sales- U.S. Revenue- Medical Surgical’ is slightly negative, with expectations of $938.99 million, indicating a decline of 0.5% year-over-year. On the other hand, ‘Net Sales- U.S. Revenue- Neuroscience- Neuromodulation’ is anticipated to be around $351.65 million, reflecting a positive change of 5.6%. Further, the estimate for ‘Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies’ is set at $326.68 million, which would be a 6.1% increase compared to last year.
Analysts also project ‘Net Sales- ROW- Neuroscience- Specialty Therapies’ to reach $319.41 million, suggesting a minimal change of 0.1% year-over-year. The anticipated figure for ‘Net Sales- ROW- Neuroscience- Neuromodulation’ is approximately $152.01 million, which signifies a year-over-year increase of 4.1%. Lastly, it is expected that ‘Net Sales- ROW- Medical Surgical- Surgical & Endoscopy’ will amount to $1.03 billion, representing a growth of 5.4% year-over-year. The combined estimate for ‘Net Sales- ROW- Cardiovascular’ is projected at $1.80 billion, indicating an increase of 7.8% from the same quarter last year.
Recent Stock Performance Overview
In the last month, Medtronic shares have experienced a modest return of 0.5%, while the broader Zacks S&P 500 composite has seen a gain of 4.6%. With a Zacks Rank of #3 (Hold), it is anticipated that MDT will perform in line with the overall market in the near future.
No coins selected
